India Antimalarial Drugs Market, By Drug Class (Aryl aminoalcohol compounds, Antifolate compounds, Artemisinin compounds, Others), By Mechanism of Action (Treatment for Malaria, Prevention from Malaria), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region, Competition, Forecast & Opportunities, 2020-2030F

Market Overview

India Antimalarial Drugs Market was valued at USD 30.15 million in 2024 and is anticipated to reach USD 38.82 Million by 2030, with a CAGR of 4.26% during 2025-2030.  

The antimalarial drugs market in India represents a significant segment within the broader pharmaceutical industry, largely due to the country’s historical and ongoing battle with malaria. Government initiatives, increased healthcare expenditure, and heightened awareness of malaria prevention and treatment. Enhanced collaboration between government entities, the private sector, and international organizations is crucial for addressing malaria more effectively. Public-private partnerships are particularly vital for improving drug distribution networks and healthcare infrastructure.

Challenges such as drug resistance and supply chain issues must be addressed to ensure sustained progress. The future outlook remains optimistic, supported by ongoing research and development, technological advancements, and collaborative efforts aimed at effectively combating malaria.

Key Market Drivers

Increasing Healthcare Expenditure

Higher healthcare expenditure allows for improved infrastructure, including healthcare facilities and distribution networks. This enables better access to antimalarial drugs in both urban and rural areas, addressing gaps in availability and affordability. Increased funding facilitates research into new antimalarial treatments and technologies. This leads to the development of more effective drugs and diagnostic tools, enhancing the overall efficacy of malaria management.

Greater financial resources support the expansion of healthcare services focused on malaria prevention, diagnosis, and treatment. This includes training healthcare professionals, establishing diagnostic centers, and ensuring adequate supply chains for antimalarial drugs. Collaboration between government agencies, pharmaceutical companies, and non-profit organizations is bolstered by increased healthcare spending. These partnerships drive innovation, improve healthcare delivery, and promote sustainable solutions for combating malaria.

Higher expenditure allows for the implementation of quality assurance measures across the supply chain. This ensures that antimalarial drugs meet regulatory standards, reducing the risk of counterfeit medications and enhancing patient safety. Investments in healthcare infrastructure, such as hospitals, clinics, and pharmacies, create a conducive environment for the distribution and administration of antimalarial drugs. This infrastructure development supports comprehensive healthcare services and contributes to overall market growth. Increasing healthcare expenditure in India plays a critical role in advancing the antimalarial drugs market by fostering innovation, improving accessibility, and enhancing the quality of care for malaria patients across the country.

Awareness and Education Campaigns

Awareness and education campaigns are playing a decisive role in India’s malaria response by improving public understanding of prevention, encouraging early diagnosis, and strengthening adherence to full treatment courses, all of which support higher treatment-seeking behavior and better control outcomes. Campaigns aimed at healthcare professionals and community workers are equally important, as the 2025 NCVBDC malaria training module for ASHAs specifically emphasizes community education on symptoms, prevention, treatment, rapid testing, follow-up, and promotion of long-lasting insecticidal nets in primary care settings.

For instance, the government’s Intensified Malaria Elimination Project 3 is targeting 159 districts across 12 states with resources for LLIN distribution, surveillance, and community-focused interventions, while Godrej Consumer Products Limited said its EMBED programme in partnership with the Madhya Pradesh government has reached 2.7 million households across 39 districts, including 10,000 villages and 3,000 slums. Stronger outreach and better monitoring are already translating into measurable progress, with India reducing malaria cases from 11,69,261 in 2015 to 2,27,564 in 2023 and deaths from 384 to 83 over the same period.

As India advances toward zero indigenous malaria cases by 2027, continued investment in localized awareness, frontline worker training, and data-backed evaluation will remain essential to refine campaign strategies, improve resource allocation, and sustain gains in malaria prevention and treatment.

Download Free Sample Report

Key Market Challenges

Drug Resistance

Drug resistance has emerged as a critical challenge for malaria control in India, as resistance to older therapies and warning signs around reduced sensitivity in some regions increase the risk of treatment failure, longer illness, and higher healthcare costs. For instance, the National Centre for Vector Borne Disease Control states that chloroquine resistance in Plasmodium falciparum was first reported in India in 1973 in Assam, and the country now monitors antimalarial response through 13 monitoring teams across 11 Regional Offices for Health and Family Welfare, with drug policy changes triggered when total treatment failure reaches 10% or more in tested cases.

India has already had to expand combination therapy in response, with artesunate plus sulfadoxine pyrimethamine being implemented across 117 high-endemic districts and 253 PHCs in 46 districts affected by chloroquine resistance and surrounding clusters. At the same time, a 2024 study involving ICMR-NIMR and international researchers analyzed more than 4,000 malaria samples and identified parts of central, eastern, and northeastern India where markers linked to sulfadoxine pyrimethamine resistance are predicted to exceed 15%, reinforcing the need for continuous surveillance and new therapeutic options. This makes sustained research, faster resistance tracking, and the development of effective next-generation antimalarial combinations essential for India even as the country reduced malaria cases from 11,69,261 in 2015 to 2,27,564 in 2023.

Supply Chain Issues

Supply chain issues remain a major barrier to effective malaria treatment in India, as inefficient distribution in remote and underserved areas can delay access to life-saving antimalarial drugs, increase the risk of stockouts and expiries, and weaken disease control efforts. For instance, India’s National Strategic Plan for Malaria Elimination 2023 to 2027, backed by an estimated budget of 6,249.80 crore rupees, specifically calls for a Logistic and Management Information System to track near real-time stock availability, while the National Centre for Vector Borne Disease Control has directed states to record stocks regularly in the DVDMS portal, closely monitor expiry, and reallocate surplus medicines so that ACT-SP, ACT-AL, and injection artesunate remain available where needed.

Strengthening supply chain infrastructure, including storage, last-mile delivery, and coordinated procurement, therefore requires stronger collaboration between government agencies and large pharmaceutical distribution networks, especially because companies such as Mankind Pharma already operate one of India’s largest medicine distribution systems with more than 13,000 stockists and about 18,000 field personnel, demonstrating the scale of private-sector reach that can support better drug access across the country.

Public Awareness and Education

Limited awareness and misconceptions about malaria prevention, symptoms, and treatment options continue to hinder control efforts in India, as delayed care seeking and incomplete treatment can weaken outcomes and allow transmission to persist. Effective public health campaigns and targeted educational initiatives are therefore essential to promote early detection, encourage preventive practices such as insecticide-treated bed nets, and improve compliance with treatment protocols in endemic communities.

For instance, India reduced malaria cases from 11,69,261 in 2015 to 2,27,564 in 2023 and brought deaths down from 384 to 83, underscoring how stronger surveillance, community engagement, and better awareness can significantly reduce disease burden. India’s National Strategic Plan for Malaria Elimination 2023 to 2027 also reinforces the importance of communication-led interventions and community participation, highlighting that higher health literacy can help households recognize symptoms earlier, seek timely treatment, and play a more active role in malaria control.

Key Market Trends

Advancements in Drug Development and Treatment Innovation

Advancements in drug development and treatment innovation are becoming increasingly important for malaria control in India, as new therapies are needed to address resistance, improve cure rates, and reduce the burden of relapse-prone infections, especially in Plasmodium vivax cases. For instance, the Indian Journal of Medical Research noted that tafenoquine is in the final stages of regulatory consideration in India, with a randomized controlled study conducted at seven Indian sites and a phase 2b and 3 study across four sites showing promising results, highlighting how newer single-dose approaches could improve treatment adherence compared with longer primaquine regimens.

Innovation is also being supported through collaborative research, with a dedicated Phase 3 tafenoquine project in India running from November 2023 to November 2026 with total funding of 2.97 million dollars, while ICMR’s 2024 to 2025 annual report states that ICMR-NIMR strengthened India’s malaria elimination efforts through vaccine innovation, vector control tools, and genetic studies. Major pharmaceutical companies are reinforcing the broader innovation ecosystem as well, with Sun Pharma investing 32 billion rupees in R&D in FY24 and Cipla spending 1,571 crore rupees on R&D in FY24, showing the scale at which large Indian drug makers are funding future pipelines, formulation science, and differentiated therapies that can support treatment innovation in infectious diseases.

Technological Integration in Healthcare Delivery

Increasing adoption of digital health technologies, telemedicine, and mobile health applications. These technologies improve access to healthcare services, facilitate remote consultations, enhance patient monitoring, and support adherence to treatment regimens.

Digital platforms will play a vital role in expanding the reach of antimalarial drugs to remote and underserved populations. Integration of data analytics and artificial intelligence (AI) will optimize disease surveillance, aid in early detection, and improve decision-making in malaria control programs.

Segmental Insights

Drug Class Insights

Based on the category of Drug Class, the Artemisinin compounds segment emerged as the dominant in the market for India Antimalarial Drugs Market in 2024. Artemisinin and its derivatives, known as Artemisinin-based Combination Therapies (ACTs), are endorsed by the World Health Organization (WHO) and Indian health authorities as the preferred first-line treatment for uncomplicated malaria due to their superior efficacy in swiftly clearing parasites from the bloodstream. This policy support is reinforced by government protocols favoring ACTs for their effectiveness in managing resistance and their wide availability through diverse distribution channels, including public health initiatives and private pharmacies. Ongoing research investments aim to enhance the safety and efficacy of Artemisinin derivatives, fostering continuous innovation in malaria treatment strategies. These factors are expected to drive the growth of this segment.

Download Free Sample Report

Regional Insights

North India emerged as the dominant in the India Antimalarial Drugs Market in 2024, holding the largest market share in terms of both value and volume. North India, particularly states like Uttar Pradesh, Bihar, Rajasthan, and Jharkhand, experiences a higher burden of malaria compared to other regions. This is attributed to factors such as climatic conditions conducive to mosquito breeding and socio-economic factors impacting healthcare access.

The prevalence of malaria drives higher demand for antimalarial drugs in North India, making it a focal point for pharmaceutical companies and healthcare providers. National and state-level malaria control programs prioritize North India due to its significant disease burden. Initiatives like the National Vector Borne Disease Control Programme (NVBDCP) focus on improving malaria diagnosis, treatment, and prevention strategies in these states. Government policies and funding allocations support the procurement and distribution of antimalarial drugs in North India, ensuring accessibility and affordability for affected populations.

North India boasts a mix of urban centers and rural areas where healthcare infrastructure, including hospitals, clinics, and pharmacies, facilitates the distribution of antimalarial drugs. Both public health institutions and private healthcare providers play crucial roles in delivering antimalarial treatments across the region, enhancing accessibility for diverse population segments. Collaborative efforts between research institutions, pharmaceutical companies, and government bodies in North India drive innovation in antimalarial drug development. The region serves as a hub for clinical research aimed at improving treatment efficacy, developing new drug formulations, and addressing challenges like drug resistance.

Recent Developments

• In December 2025, the National Center for Vector Borne Diseases Control announced decentralized procurement of anti-malaria drugs including ACT-SP, ACT-AL, and injectable artesunate under NCVBDC, indicating continued institutional demand for these therapies in India.
• In November 2025, Mangalam Drugs & Organics said it received a repeat export order worth about Rs 15 crore for an anti-malarial API from an overseas client, marking a notable company update for an Indian antimalarial manufacturer.
• In May 2024 - Scientists from Jawaharlal Nehru University (JNU) have identified a promising vaccine candidate for malaria, targeting the parasite's Prohibitin protein. Published in the iScience journal by Cell Press, their research aims to advance more effective prevention and treatment strategies against the disease, which continues to pose a significant public health challenge globally, including in India.

Key Market Players

• CiplaLtd
• Sun Pharmaceutical Industries Ltd
• Glenmark Pharmaceuticals Ltd
• Strides Pharma Science Ltd
• Ipca Laboratories Ltd
• Aurobindo Pharma Ltd
• Alkem Laboratories Ltd
• Novartis India Ltd
• Lupin Limited
• Cadila Healthcare Ltd

Report Scope:

In this report, the India Antimalarial Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• India Antimalarial Drugs Market, By Drug Class:

o   Aryl aminoalcohol compounds

o   Antifolate compounds

o   Artemisinin compounds

o   Others

• India Antimalarial Drugs Market, By Mechanism of Action:

o   Treatment for Malaria

o   Prevention from Malaria

• India Antimalarial Drugs Market, By Distribution Channel:

o   Hospital Pharmacy

o   Retail Pharmacy

o   Online Pharmacy

• India Antimalarial Drugs Market, By Region:

o   North India

o   South India

o   East India

o   West India

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the India Antimalarial Drugs Market.

Available Customizations:

 India Antimalarial Drugs market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

 India Antimalarial Drugs Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]